myelodysplastic syndrome with excess blasts
Conditions
Interventions
Group 1:Homoharringtonine combined with cytarabine and Peg-Dox and recombinant human granulocyte colony-stimulating factor
Group 2:Decitabine?Homoharringtonine combined with cytarabine and recombinant human granulocyte colony-stimulating factor
Sponsors
Department of Hematology, Xinqiao Hospital, Army Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Sign an informed consent form; 2. the Male or Female aged 18 to 70 years; 3. The patients with MDS-EB with pathology,histology or flow cytometry with bone marrow; 4. The estimated survival is over three months; 5. Adequate main organ function: (1) Liver: ALT/AST 40 %; 6. Karnofsky >=60 at study entry.
Exclusion criteria
Exclusion criteria: 1. Pregnant or breastfeeding female subject; 2. Drug abusers; 3. uncontrolled infection 4 weeks before enrolled; 4. Known positive for HIV or acute infectious hepatitis, type A, B or C; 5. other primary tumor except for AML; 6. Serious autoimmune disease or mmune deficiency disorder; 7. Central nervous involvement; 8. Serious psychiatric or psychological disorders; 9. Patients can not be enrolled which will be judged by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of complete remission; | — |
Secondary
| Measure | Time frame |
|---|---|
| Rate of minimal residual disease negativity;2-year DFS;2-year OS;Complications;Objective response rate; | — |
Countries
China
Contacts
Public ContactZhang Xi
Department of Hematology, Xinqiao Hospital, Army Medical University, Chongqing
Outcome results
None listed